Generate Biomedicines Quarterly Balance Sheet
NASDAQ: GENBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Generate Biomedicines financial position
As of Jun 30, 2026, Generate Biomedicines reported total assets of $561.7 million against total liabilities of $105.6 million. Shareholders' equity stood at $456.0 million, or 81.2% of assets. The company held $135.4 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 8.30, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Generate Biomedicines balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Cash & Equivalents | 135.36M | 160.57M | 154.26M | 220.61M |
| Short-Term Investments | 322.06M | 356.07M | — | — |
| Total Current Assets | 470.25M | 535.39M | — | — |
| Property, Plant & Equipment | 27.30M | 27.84M | — | — |
| Total Assets | 561.69M | 625.74M | — | — |
| Accounts Payable | 5.65M | 7.62M | — | — |
| Total Current Liabilities | 56.64M | 58.39M | — | — |
| Total Liabilities | 105.64M | 110.94M | — | — |
| Shareholders' Equity | 456.05M | 514.80M | -517.85M | -471.00M |
| Retained Earnings | -804.99M | -737.74M | — | — |
| Net Cash (Debt) | 457.42M | 516.64M | 154.26M | 220.61M |
| Shares Outstanding | 128.27M | 128.19M | — | — |
This table shows 4 quarterly periods of Generate Biomedicines's balance sheet, from Q2 2026 back to Q? 2025, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow GENB's reporting calendar. What is a balance sheet?